Various lipid metabolism pathways influenced by omega-3 polyunsaturated fatty acids

Omega-3 polyunsaturated fatty acids (PUFAs), most notably EPA, DHA, and ALA, exert their effects through various lipid metabolism pathways. These include enzymatic conversion by desaturases, elongases, cyclooxygenases, lipoxygenases, and cytochrome P450s, resulting in bioactive lipid mediators like resolvins, protectins, and maresins, which play crucial roles in anti-inflammatory signaling and vascular function. Omega-3 fatty acids modulate cholesterol, triglyceride, and lipoprotein profiles and have established therapeutic benefits targeting diseases such as hypertriglyceridemia, cardiovascular disease, neurodegenerative disorders, and chronic inflammation. They are available as prescription drugs (icosapent ethyl, omega-3-acid ethyl esters) approved for severe hypertriglyceridemia. This therapeutic class operates by altering enzyme activities, cell membrane composition, and signal transduction, and is tracked clinically with lipid profile biomarkers. Safety concerns include potential elevation of LDL cholesterol and bleeding risk, especially at pharmacological doses[1][3][4][7].

Other names

Omega-3 PUFA-regulated lipid pathwaysOmega-3 fatty acid metabolic regulationn-3 PUFA metabolic pathways

Modulation of lipid oxidation and synthesis (e.g., reduced triglyceride synthesis, increased β-oxidation[1][3][5]); Substrate for bioactive lipid mediators (conversion to resolvins, protectins, maresins for anti-inflammatory effect[3][7]); Decreased production of pro-inflammatory eicosanoids (via altered COX/LOX activity[3]); Alteration of lipoprotein profiles (decreases VLDL, changes LDL subclass composition[1][4])